Amplia Therapeutics Ltd (ASX: ATX) — Healthcare · Share Price, Chart & Market Data
About: Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.17 (+3.03%)
ATXAmplia Therapeutics Ltd
Loading watchlist status…
Trade ATX now
Amplia Therapeutics Ltd share price
ATX price activity
Last Price
Change (24hr)
AUD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 12:02 pm GMT+0
ATX price performance
9.677%
5D
-30.612%
1M
0%
YTD
214.815%
1Y
ATX price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
ASX rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 12:02 pm GMT+0
ATX details
ATX Market Signals